Aligos (ALGS) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$31.5M

Revenue (quarter)

$27.8M

Revenue growth (year over year)

+2778.55%

Gross profit (trailing twelve months)

$31.5M

Gross margin

100.00%

Net income (trailing twelve months)

−$76.0M

Net income (quarter)

−$1.5M

Net income growth (year over year)

+90.52%

Net margin

−241.01%

Return on equity

−113.59%

EPS (trailing twelve months)

−$7.71

Book value per share

$5.11

P/E (trailing twelve months)

—

Price to book

1.04

Debt to assets

51.93%

Payout ratio

—

Dividend yield

—

Company profile

Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.

• Is Aligos (ALGS) profitable?

  No. Aligos reported a net loss of $76.0M over the trailing twelve months.

• How much revenue does Aligos (ALGS) make?

  Aligos generated $31.5M in revenue over the trailing twelve months, up 2778.55% year over year.

• How do I buy stock in Aligos (ALGS)?

  ALGS trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.